Excited to see Destiny Breast 03 now published in NEJM! T-DXd is the current 2L standard of care for metastatic HER2+ breast cancer, and more to come from this agent in the future!
@OncoAlert #bcsm
Sara Tolaney
@stolaney1
Boston. MA
Joined December 2015
